Jon Faldasz/LinkedIn
Nov 21, 2025, 08:55
Jon Faldasz: Why Aren’t We Better at Achieving Therapeutic Warfarin Control?
Jon Faldasz, Senior Director of Product and Customer Experience at InsightRX, posted on LinkedIn:
”Ok I know warfarin is the stinky kid in the corner, but it’s not going anywhere. So why aren’t we better at achieving time in therapeutic range?
Could it be:
– We think that 40% time in range is “good enough”? (data argues otherwise)
– Low warfarin use means we think this problem isn’t significant (patients would argue otherwise)
– We think that the problem is unsolvable? (Anticoagulation specialists argue otherwise)
I would love to get some comments to bring with me to the Anticoagulation Forum Stewardship Summit. Don’t make me call you out, people.”
Stay updated with Hemostasis Today.
-
Mar 12, 2026, 20:44Honoring Marion Stolte’s Lasting Impact on the Bleeding Disorders Community – WFH
-
Mar 12, 2026, 20:37Paul Riley: Is Thrombin Generation Assay Ready for Prime Time?
-
Mar 12, 2026, 20:28Rob Maloney: Building Visibility for Bleeding Disorders in Rural Georgia
-
Mar 12, 2026, 20:19Akshat Jain: Validating Oral Pain Medication Use as a Global Marker in Sickle Cell Disease
-
Mar 12, 2026, 20:13Michael Makris: Early Clinical Results of AAV8-BDD FVIII Gene Therapy in Hemophilia A
-
Mar 12, 2026, 20:02Wolfgang Miesbach: From Heparin to Vaccines – The Expanding Biology of Anti-PF4 Immunothrombosis
-
Mar 12, 2026, 19:56Christophe Dubois: Celebrating Nicolas Gendron’s HDR Defense and Future in Hemostasis
-
Mar 12, 2026, 17:06Caitlin Raymond: Managing Crigler–Najjar Syndrome Type 1 Crisis Without a Standard TPE Protocol
-
Mar 12, 2026, 17:03Jan Sloves: Insights on Comprehensive Venous Duplex Imaging at VEITH Symposium 2025